[1]欧阳韧韧,白　欢,沈　玲,等.新型冠状病毒肺炎患者入院血糖水平对其预后评估的临床价值研究[J].现代检验医学杂志,2022,37(01):172-176.[doi:10.3969/j.issn.1671-7414.2022.01.035]
　OUYANG Ren-ren,BAI Huan,SHEN Ling,et al.Clinical Value of Admission Blood Glucose Level on Prognosis of COVID-19 Patients[J].Journal of Modern Laboratory Medicine,2022,37(01):172-176.[doi:10.3969/j.issn.1671-7414.2022.01.035]
点击复制

新型冠状病毒肺炎患者入院血糖水平对其预后评估的临床价值研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年01期
页码:
172-176
栏目:
新型冠状病毒肺炎检验专题
出版日期:
2022-01-15

文章信息/Info

Title:
Clinical Value of Admission Blood Glucose Level on Prognosis of COVID-19 Patients
文章编号:
1671-7414（2022）01-172-06
作者:
欧阳韧韧; 白　欢; 沈　玲; 龚　路; 曾浩龙; 刘为勇; 张　驰
（华中科技大学同济医学院附属同济医院检验科，武汉 430030）
Author(s):
OUYANG Ren-ren; BAI Huan; SHEN Ling; GONG Lu; ZENG Hao-long; LIU Wei-yong; ZHANG Chi
（Department of Clinical Laboratory, Tongji Hospital, Tongji Medical College, Huazhong University ofScience and Technology, Wuhan 430030, China）
关键词:
新型冠状病毒肺炎; 高血糖; 糖尿病; 预后
分类号:
R563.14；R446.112
DOI:
10.3969/j.issn.1671-7414.2022.01.035
文献标志码:
A
摘要:
目的　探讨新型冠状病毒肺炎患者入院血糖水平对其预后评估的临床价值。方法　选取 2020年 1月 18日～ 2月 26日序贯入住华中科技大学同济医学院附属同济医院明确诊断为新型冠状病毒肺炎（ COVID-19）的 420例患者为研究对象，记录是否并发糖尿病、入院首次血糖水平和入院时临床分型及院内死亡事件等资料，依据是否并发糖尿病分为糖尿病组与非糖尿病组，入组后根据院内死亡事件分为生存亚组与死亡亚组，根据临床分型分为普通型亚组、重型亚组与危重型亚组，分析比较组内各亚组间入院血糖水平的差异，另根据入院血糖水平（ GLU）分为 GLU 3.9~7.8mmol/L亚组、
Abstract:
Objective　To explore the clinical value of admission blood glucose level on prognosis of COVID- 19 patients.Methods　A total of 420 novel coronavirus pneumonia (COVID-19) patients admitted to Tongji Hospital of Tongji MedicalCollege from January 18, 2020 to February 26, 2020 were selected as the subjects of study. The data of diabetes or not,admissionblood glucose level(GLU), clinical severity grade were collected through the electronic medical record system,and the outcome,which defined as in-hospital motality, was also monitored. The patients were divided into diabetes group and non-diabetes groupin terms of the complication of diabetes, and then, firstly, stratified these two groups into survival subgroup and non-survivalsubgroup in according to the event of in-hospital motality, GLU between these two subgroups were compared.Secondly,according to the clinical severity grade, these two groups were stratified into moderate subgroup, severe subgroup and criticalsubgroup, and GLU among these subgroups were also compared. Thirdly, according to the admission blood glucose level,stratified these two groups into GLU 3.9~7.8 mmol /L subgroup,GLU 7.8~10.0mmol/L subgroup and GLU>10.0mmol/Lsubgroup, the in-hospital motality rates among these subgroups were compared. Finally,the multivariate logistic regression wasused to explore whether increased GLU were independent risk factor for in-hospital motality in diabetes group and non-diabetesgroup when adjusted for sex, age and underlying disease. Results　In non-diabetes group,compared with Survival subgroup,GLUwas significantly elevated in non-Survival subgroup[6.96（5.95, 8.23）mmol/L vs 5.96 (5.32, 6.92) mmol/L],the difference wasstatistically significant（U=6047.0, P<0.001）, but in diabetes group,there was no significant difference between non-survivalsubgroup and Survival subgroup [12.42(8.41, 18.17) mmol/L vs 9.88 (7.79, 14.02) mmol/L], the difference was statisticallysignificant（U=1 200.5, P=0.059）.In Non-diabetes group, GLU elevated remarkably along with the clinical severity gradeincreased, moderate subgroup, severe subgroup, critical subgroup GLU were 5.87(5.24, 6.69) mmol/L, 6.94(5.95, 7.90) mmol/L,9.73 (6.22, 11.64) mmol/L, the difference were statistically significant, respectively(U=723.0~4978.0,all P<0.01). However indiabetes group,there was no significant difference on GLU when the clinical severity grade increased, moderate subgroup, severesubgroup, critical subgroup GLU were 9.88（7.81, 11.93）mmol/L, 12.42（8.43, 16.94）mmol/L, 11.43(7.89, 18.76)mmol/L,the difference were statistically significant ，respectively (U=262.0~946.5, all P>0.05).In non-diabetes group, GLU> 10.0 mmol/L subgroup had the hightest in-hospital motality rate (72.0%) among all three subgroups, the differences were statisticallysignificant（χ2=24.607, 9.625, all P<0.01）, when compared between GLU 3.9~7.8mmol/L subgroup (in-hospital motality rate24.8%) and GLU 7.8~10.0mmol/L subgroup (in-hospital motality rate 30.0%), there was no significant difference on in-hospitalmotality rate (χ2=0.383, P > 0.05).However, in diabetes group, along with GLU increased, it had no significant difference on inhospitalmotality rate, GLU 3.9~7.8mmol/L subgroup, GLU 7.8~10.0mmol/L subgroup, GLU> 10.0mmol/L subgroup, the inhospitalmotality rate were 34.8%, 41.4%, 49.2%, respectively(χ2=0.236~1.380, all P> 0.05). Multivariate logistic regressionshowed, in non-diabets group, GLU>10.0 mmol/L was the independent risk factor when adjusted for sex, age and underlyingdisease,odds ratio was 7.969, and 95% confidence interval was 3.022~21.013,but in diabets group.It seemed that GLU>10.0mmol/L was not the independent risk factor. Conclusion　Admission blood glucose is a good predictor for disease severity andoutcome in non-diabetes patients with COVID-19. When admission hyperglycemia occurs, it tends to predict a poor prognosis.

参考文献/References:

[1] 刘茜, 王荣帅, 屈国强, 等．新型冠状病毒肺炎死亡尸体系统解剖大体观察报告[J]．法医学杂志, 2020,36（1）：21-23．LIU Qian,WANG Rongshuai,QU Guoqiang, etal.General observation of systemic autopsy of aCOVID-19 death[J]. Journal of Forensic Medicine,2020,36(1):21-23.
[2] YANG Xiaobo, YU Yuan, XU Jiqian, et al. Clinicalcourse and outcomes of critically ill patients withSARS-CoV-2 pneumonia in Wuhan, China: a singlecentered,retrospective, observational study[J]. TheLancet Respiratory Medicine, 2020, 8(5): 475-481.
[3] YANG J K, FENG Y, YUAN M Y, et al. Plasmaglucose levels and diabetes are independent predictorsfor mortality and morbidity in patients with SARS[J].Diabetic Medicine, 2006, 23(6): 623-628.
[4] VAN VUGHT L A, WIEWEL M A, KLEINKLOUWENBERG P M et al. Admission hyperglycemiain critically ill sepsis patients: association with outcomeand host response[J]. Critical Care Medicine, 2016,44(7): 1338-1346.
[5] CHEN Nanshan, ZHOU Min, DONG Xuan, et al.Epidemiological and clinical characteristics of 99cases of 2019 novel coronavirus pneumonia in Wuhan,China: a descriptive study[J]. Lancet, 2020, 395(1223):507-513.
[6] LI Xiaochen, XU Shuyun, YU Muqing, et al. Riskfactors for severity and mortality in adult COVID-19inpatients in Wuhan[J]. The Journal of Allergy andClinical Immunology, 2020, 146(1): 110-118.
[7] 中华人民共和国国家卫生健康委员会. 国卫办医函〔2020〕184 号：关于印发新型冠状病毒肺炎诊疗方案( 试行第七版)[EB/OL].(2020-03-03)[2020-03-08]. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml．National Health Commission of the People’s Republicof China .Medical Letter of the State Health Office[2020] No. 184: Notification on the issuance ofCOVID-19 medical program (trial seventh edition) [EB/OL].（2020-03-03）[2020-03-08]. http://www.nhc.gov.cn/yzygj/ s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml．
[8] World Health Organization. Use of glycatedhaemoglobin ( HbA1c) in the diagnosis of diabetesmellitus. Abbreviated report of a WHO consultation[ R].Geneva: World Health Organization,2011.
[9] M O G H I S S I E S , K O RYTKOWSKI M T,DINARDO M, et al. American association of clinicalendocrinologists and American diabetes associationconsensus statement on inpatient glycemic contro[J].Diabetes Care, 2009, 32(6): 1119-1131.
[10] MARIK P E, BELLOMO R. Stress hyperglycemia:an essential survival response[J]. Critical Care, 2013,17(2): 305.
[11] DUNGAN K M, BRAITHWAITE S S, PREISER J C.Stress hyperglycaemia[J]. Lancet, 2009, 373(9677):1798-1807.
[12] UMPIERREZ G E, ISAACS S D, BAZARGANN, et al. Hyperglycemia: an independent marker ofin-hospital mortality in patients with undiagnoseddiabetes[J]. The Journal of Clinical Endocrinology andMetabolism, 2002, 87(3): 978-982.
[13] GODINJAK A, IGLICA A, BUREKOVIC A, et al.Hyperglycemia in critically ill patients: managementand prognosis[J]. Medical Archives (Sarajevo, Bosniaand Herzegovina), 2015, 69(3): 157-160.
[14] ZHOU Peng, YANG Xinglou, WANG Xianguang,et al. A pneumonia outbreak associated with a newcoronavirus of probable bat origin[J]. Nature, 2020,579(7798): 270-273.
[15] YANG Jinkui, LIN Shanshan, JI Xiujuan, et al. Bindingof SARS coronavirus to its receptor damages islets andcauses acute diabetes[J]. Acta Diabetologica, 2010,47(3): 193-199.
[16] ILIAS I, ZABULIENE L. Hyperglycemia and thenovel Covid-19 infection: Possible pathophysiologicmechanisms[J].Medical Hypotheses, 2020, 139:109699.
[17] RAGAB D, ELDIN H S, TAEIMAH M, et al. TheCOVID-19 cytokine storm; what we know so far[J].Frontiers in Immunology, 2020, 11: 1446.
[18] CHROUSOS G P. The hypothalamic-pituitary-adrenalaxis and immune-mediated inflammation[J]. The NewEngland Journal of Medicine, 1995, 332(20): 1351-1362.
[19] LING P R, SMITH R J, BISTRIAN B R. Hyperglycemiaenhances the cytokine production and oxidativeresponses to a low but not high dose of endotoxin inrats[J].Crit Care Med,2005,33(5): 1084-1089.
[20] YU Wenkui, LI Weiqin, LI Ning, et al. Influenceof acute hyperglycemia in human sepsis oninflammatory cytokine and counterregulatory hormoneconcentrations[J]. World Journal of Gastroenterology,2003, 9(8): 1824-1827.
[21] BUTLER S O, BTAICHE I F, ALANIZ C. Relationshipbetween hyperglycemia and infection in criticallyill patients[J]. Pharmacotherapy, 2005, 25(7): 963-976.
[22] DIEBEL L N, LIBERATI D M, MARTIN J V. Acutehyperglycemia increases sepsis related glycocalyxdegradation and endothelial cellular injury: Amicrofluidic study[J]. American Journal of Surgery,2019, 217(6): 1076-1082.
[23] GUO Weina, LI Mingyue, DONG Yalan, et al. Diabetesis a risk factor for the progression and prognosis ofCOVID-19[J]. Diabetes-Metabolism: Research andReviews, 2020, 36(7): e3319.
[24] American Diabetes Association. Diagnosis andclassification of diabetes mellitus[J]. Diabetes Care,2014, 37(Suppl 1): S81-S90.
[25] DU Ronghui, LIANG Lirong, YANG Chengqing, etal. Predictors of mortality for patients with COVID-19pneumonia caused by SARS-CoV-2: a prospectivecohort study[J]. The European Respiratory Journal,2020, 55(5): 2000524.
[26] 白欢, 沈玲, 陈星, 等.PT, DD 和PLT 在新型冠状病毒肺炎重症患者预后评估及基于SIC 积分系统指导抗凝治疗的价值研究[J]. 中华检验医学杂志,2020,43 (12):1205-1211.BAI Huan, SHEN Ling, CHEN Xing, et al. Theprognosis value of PT, DD and PLT and validation ofthe efficacy of the SIC score on initiating anticoagulanttherapy in severe COVID-19 patients[J]. ChineseJournal of Laboratory Medicine ,2020,43 (12):1205-1211.
[27] ZHOU Fei, YU Ting, DU Ronghui, et al. Clinicalcourse and risk factors for mortality of adult inpatientswith COVID-19 in Wuhan, China: a retrospectivecohort study[J]. The Lancet, 2020, 395(1229): 1054-1062.
[28] ZHAO Yu, ZHAO Zixian, WANG Yujia, et al. SinglecellRNA expression profiling of ACE2, the receptor ofSARS-CoV-2[J]. American Journal of Respiratory andCritical Care Medicine, 2020, 202(5): 756-759.

相似文献/References:

[1]汪衍民.应用质谱技术探究血液中游离脂肪酸与高血糖病症之间的关系[J].现代检验医学杂志,2018,33(05):12.[doi:10.3969/j.issn.1671-7414.2018.05.004]
　WANG Yan-min.Relationship between Probing Blood Free Fatty Acids and Hyperglycemia Using Mass Spectrometry[J].Journal of Modern Laboratory Medicine,2018,33(01):12.[doi:10.3969/j.issn.1671-7414.2018.05.004]
[2]谢　辉,刘玮玮b,郭　娟a,等.新型冠状病毒肺炎疫情下检验医学临床服务管理的探索[J].现代检验医学杂志,2020,35(03):81.[doi:10.3969/j.issn.1671-7414.2020.03.020]
　XIE Huia,LIU Wei-weib,GUO Juana,et al.Exploration on Clinical Service Management of Laboratory Medicine during COVID-19 Epidemic Period[J].Journal of Modern Laboratory Medicine,2020,35(01):81.[doi:10.3969/j.issn.1671-7414.2020.03.020]
[3]朱传新,周玉平,何　艳,等.92 例新冠肺炎病毒感染患者早期外周血白细胞形态分析[J].现代检验医学杂志,2020,35(03):94.[doi:10.3969/j.issn.1671-7414.2020.03.024]
　ZHU Chuan-xin,ZHOU Yu-ping,HE Yan,et al.Morphological Analysis of Early Peripheral Blood Leukocytes in 92 Patients with New Coronary Pneumonia[J].Journal of Modern Laboratory Medicine,2020,35(01):94.[doi:10.3969/j.issn.1671-7414.2020.03.024]
[4]刘艳霞,区静怡,黄 颖,等.新型冠状病毒肺炎患者外周血淋巴细胞及其亚群检测的临床意义[J].现代检验医学杂志,2020,35(04):94.[doi:10.3969/j.issn.1671-7414.2020.04.023]
　LIU Yan-xia,OU Jing-yi,HUANG Ying,et al.Clinical Significance of Detection of Peripheral Blood Lymphocyte and Its Subgroups in Patients with Coronavirus Disease 2019[J].Journal of Modern Laboratory Medicine,2020,35(01):94.[doi:10.3969/j.issn.1671-7414.2020.04.023]
[5]佟 丽,黄丽萍,石晓霞,等.血栓弹力图检测新型冠状病毒肺炎患者凝血功能的探讨分析[J].现代检验医学杂志,2020,35(04):97.[doi:10.3969/j.issn.1671-7414.2020.04.024]
　TONG Li,HUANG Li-ping,SHI Xiao-xia,et al.Investigation and Analysis of Thromboelastography in the Detection of COVID-19 Patients[J].Journal of Modern Laboratory Medicine,2020,35(01):97.[doi:10.3969/j.issn.1671-7414.2020.04.024]
[6]朱旭阳,叶寒青,陈文亥,等.新型冠状病毒肺炎患者血清SARS-CoV-2 抗体的检测分析[J].现代检验医学杂志,2020,35(04):106.[doi:10.3969/j.issn.1671-7414.2020.04.026]
　ZHU Xu-yang,YE Han-qing,CHEN Wen-hai,et al.Preliminary Analysis of Serum Antibodies Against SARS-CoV-2 in Patient with Coronavirus Disease 2019[J].Journal of Modern Laboratory Medicine,2020,35(01):106.[doi:10.3969/j.issn.1671-7414.2020.04.026]
[7]白欢,沈玲,袁旭,等.新型冠状病毒肺炎患者早期外周血实验室检查结果分析[J].现代检验医学杂志,2020,35(05):93.[doi:10.3969/j.issn.1671-7414.2020.05.024]
　BAI Huan,SHEN Ling,YUAN Xu,et al.Analysis of the Characteristics of Hematological Parameters in the Early Stages of COVID-19[J].Journal of Modern Laboratory Medicine,2020,35(01):93.[doi:10.3969/j.issn.1671-7414.2020.05.024]
[8]张园,周泽奇,王志贤,等.新型冠状病毒核酸、抗原和抗体联合检测的临床价值讨论[J].现代检验医学杂志,2020,35(05):99.[doi:10.3969/j.issn.1671-7414.2020.05.025]
　ZHANG Yuan,ZHOU Ze-qi,WANG Zhi-xian,et al.Discussion on the Clinical Value of Combined Detection of SARS-CoV-2 Nucleic Acid，Antigen and Antibody[J].Journal of Modern Laboratory Medicine,2020,35(01):99.[doi:10.3969/j.issn.1671-7414.2020.05.025]
[9]陈赛,刘海艇,李铁,等.新型冠状病毒肺炎患者肝功能异常的相关临床分析[J].现代检验医学杂志,2020,35(05):103.[doi:10.3969/j.issn.1671-7414.2020.05.026]
　CHEN Sai,LIU Hai-ting,LI Tie,et al.Clinical Analysis of Abnormal Liver Function in Patients with New Coronavirus Pneumonia[J].Journal of Modern Laboratory Medicine,2020,35(01):103.[doi:10.3969/j.issn.1671-7414.2020.05.026]
[10]闫美田,郑雨桐,孙艳美,等.新型冠状病毒肺炎患者血液CRP, CREA, ALB, IL-6 水平检测对疾病预后的应用价值分析[J].现代检验医学杂志,2020,35(05):106.[doi:10.3969/j.issn.1671-7414.2020.05.027]
　YAN Mei-tian,ZHENG Yu-tong,SUN Yan-mei,et al.Analysis of the Value of Detection of Blood CRP,CREA,ALB and IL-6 Level in Patients with New Coronavirus Pneumonia to the Prognosis of the Disease[J].Journal of Modern Laboratory Medicine,2020,35(01):106.[doi:10.3969/j.issn.1671-7414.2020.05.027]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金青年科学基金项目（编号：31600666）。
作者简介：欧阳韧韧（1994-），女，全日制本科，检验技师，研究方向：临床检验诊断学，E-mail:872442321@qq.com。
通讯作者：白欢（1987-），男，本科，主管技师，E-mail:huanzi1987_hust@163.com。
更新日期/Last Update: 1900-01-01